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Abstract
Although proteinacious in nature, prions exist as strains with specific self-perpetuating biological properties. Prion strains
are thought to be associated with different conformers of PrP
Sc, a disease-associated isoform of the host-encoded cellular
protein (PrP
C). Molecular strain typing approaches have been developed which rely on the characterization of protease-
resistant PrP
Sc. However, PrP
Sc is composed not only of protease-resistant but also of protease-sensitive isoforms. The aim of
this work was to develop a protocol for the molecular characterization of both, protease-resistant and protease-sensitive
PrP
Sc aggregates. We first set up experimental conditions which allowed the most advantageous separation of PrP
C and
PrP
Sc by means of differential centrifugation. The conformational solubility and stability assay (CSSA) was then developed by
measuring PrP
Sc solubility as a function of increased exposure to GdnHCl. Brain homogenates from voles infected with
human and sheep prion isolates were analysed by CSSA and showed strain-specific conformational stabilities, with mean
[GdnHCl]1/2 values ranging from 1.6 M for MM2 sCJD to 2.1 for scrapie and to 2.8 M for MM1/MV1 sCJD and E200K gCJD.
Interestingly, the rank order of [GdnHCl]1/2 values observed in the human and sheep isolates used as inocula closely
matched those found following transmission in voles, being MM1 sCJD the most resistant (3.3 M), followed by sheep scrapie
(2.2 M) and by MM2 sCJD (1.6 M). In order to test the ability of CSSA to characterise protease-sensitive PrP
Sc, we analysed
sheep isolates of Nor98 and compared them to classical scrapie isolates. In Nor98, insoluble PrP
Sc aggregates were mainly
protease-sensitive and showed a conformational stability much lower than in classical scrapie. Our results show that CSSA is
able to reveal strain-specified PrP
Sc conformational stabilities of protease-resistant and protease-sensitive PrP
Sc and that it is
a valuable tool for strain typing in natural hosts, such as humans and sheep.
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Introduction
Transmissible spongiform encephalopathies (TSEs), or prion
diseases, are neurodegenerative disorders that afflict humans and
others mammals. TSEs may have genetic, infectious, or sporadic
origins. Creutzfeldt-Jakob disease (CJD) is the most common TSE
in humans and may be sporadic (sCJD), genetic (gCJD), or
acquired (iatrogenic CJD). A novel human acquired prion disease,
variant CJD (vCJD), appeared from 1995 onwards and was
postulated to be caused by consumption of beef from cows infected
with bovine spongiform encephalopathy (BSE). The most common
forms of TSE in animals, scrapie in small ruminants, BSE in cattle
and chronic wasting disease (CWD) in deer, are all acquired. New
atypical forms of BSE in cattle, namely BSE-H [1] and BSE-L or
BASE [2] and atypical scrapie in small ruminants, namely Nor98
[3], are supposed to be sporadic.
All TSEs are characterised by the accumulation of PrP
Sc,a
misfolded form of the cellular protein PrP
C. Besides differing in
conformation, the two forms of the prion protein have divergent
physical properties: while PrP
C is soluble in nondenaturating
detergents, rapidly digested by proteases, and rich in a-helical
structure, PrP
Sc is insoluble in detergents, partially resistant to
proteolysis and contains mostly b-sheet [4,5,6].
A major problem for the protein-only hypothesis, which
postulates that prions are composed mainly or exclusively of
PrP
Sc [7], was to explain the existence of multiple strains of prions.
Prion strains are infectious isolates that, when propagated in the
same host, exhibit distinct prion disease phenotypes that persist
upon serial transmission [8,9,10]. Thus, prion strains cannot be
encoded by differences in PrP primary structure but anyway carry
information that are independent from the host [11]. The prion
hypothesis equates strains to different self-propagating conforma-
tional variants of PrP
Sc [12].
Several studies demonstrated that prion strains can be
distinguished based on different biochemical properties of PrP
Sc,
thus allowing a molecular strain typing approach to TSEs. These
studies are based on the electrophoretic features of the protease
resistant core of PrP
Sc [13,14,15], the relative proteinase K
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Sc [16,17,18], or the physico-chemical behaviour
of PrP
Sc during denaturation [19,20] and strongly support the
view that distinct strains show different PrP
Sc conformations.
A conformational stability assay (CSA), combining guanidine
hydrochloride (GdnHCl) denaturation with limited proteolysis
using proteinase K, showed that different prion strains may exhibit
distinct denaturation profiles [20]. A conformation-dependent
immunoassay (CDI) showed the existence of multiple strain-
specified PrP
Sc conformers by quantifying the immunoreactivity of
native and denatured PrP
Sc of eight hamster prion isolates [19].
This technique also showed that prion-infected brains contain
both protease-sensitive (sPrP
Sc) and protease-resistant PrP
Sc
(rPrP
Sc). More recently, it was shown by CDI that sPrP
Sc
represents as much as 90% of total PrP
Sc in the brain of patients
with sporadic CJD [21].
These findings along with the recent discovery in humans [22]
and animals [3] of previously undetected TSEs characterised by
relatively protease sensitive PrP
Sc, highlights the need of molecular
strain typing methods able to recognize PrP
Sc populations based
on their physical properties rather than only based on protease
digestion.
In this study we aimed at developing a new conformational
stability assay based on the differential solubility of PrP
C and PrP
Sc
[23,24], that we called CSSA (conformational stability and
solubility assay). We have previously transmitted CJD and scrapie
isolates to bank voles [25,26], which showed to be a valuable tool
for the biological characterization of the most common forms of
sCJD, gCJD and scrapie. We took advantage of these vole-adapted
strains in order to evaluate the potential of CSSA for strain
discrimination.
We first set up experimental conditions allowing the most
advantageous separation of PrP
C and PrP
Sc, and thus performed
the conformational stability assay by measuring PrP
Sc solubility in
homogenates treated with increasing concentrations of GdnHCl in
the absence of proteinase K. Indeed, insoluble PrP was inversely
correlated to GdnHCl concentration, and dose-response curves
allowed estimation of the concentration of GdnHCl able to
solubilise 50% of PrP
Sc.
Additionally, we extended the study to natural isolates of sheep
scrapie and human sCJD cases to investigate the potential of
CSSA for strain discrimination in natural hosts. Our results show
that this method is valuable for the biochemical typing of strains in
voles and it is also a promising tool for molecular analysis of
natural prion isolates.
Results
PrP species in healthy and diseased brain
It has been previously reported that normal PrP is composed of
full-length PrP (FL-PrP) as well as of 2 C-terminal fragments
derived from physiological cleavage at the a and b sites: C1, which
is the most represented, derives from a PrP cleavage at position
111/112, while C2 is usually barely detectable and is cleaved
around the octarepeat region [27]. Interestingly, a cleavage
disrupts the conserved neurotoxic and amyloidogenic region
comprising residues 106–126 of PrP, preventing the generation
of PrP
Sc, while b cleavage occurs upstream this conserved region.
Accordingly, C2 was reported to be enriched in diseased brains
and insoluble in nondenaturing detergents, similarly to PrP
res [28].
In order to determine if C1 and C2 were detectable in voles, we
analysed healthy and diseased brain homogenates either before or
after deglycosylation, with SAF84, whose epitope is present in both
fragments, and 12B2 which recognises an epitope that is present
only in C2 (Fig. 1A). In normal brain homogenate (NBH), FL-PrP
was accompanied by substantial amounts of C1 and lower
amounts of C2. In contrast, in voles infected with the Italian
scrapie isolate SS7 (SBH) [26] C2 was strongly enhanced while C1
was not easily detectable (Fig. 1B and C). Furthermore, the PrP
res
fragment generated after PK digestion in SBH was similar to C2
(Fig. 1B and C). Finally, in SBH PrP dimers were present which
were completely absent in NBH.
Separation of PrP
C and PrP
Sc
In order to develop a conformational stability assay based on the
differential solubility of PrP
C and PrP
Sc we first set up the
experimental conditions which enabled the most advantageous
separation of PrP
C from PrP
Sc. This was obtained through a
conventional procedure based on centrifugation in the presence of
detergents.
By varying concentrations of different detergents, times of
centrifugation and centrifugal force (see Material and Methods),
we found that treatment with 2% sarcosyl followed by centrifu-
gation at 20.000 g for 1 h enabled an optimal separation of PrP
C
from PrP
Sc.
In these conditions, .95% of the total PrP
C in NBH was soluble
and was found in the supernatant fraction (Fig. 2A, left panel)
while in SBH most of PrP was sedimented (Fig. 2A, right panel).
Unfractionated SBH contained high amounts of PrP
res which
exclusively sedimented to the pellet fraction (Fig.2A). Insoluble PrP
from SBH was indeed mostly PK-resistant (,90% of insoluble
PrP), while soluble PrP was PK-sensitive. All fractions from NBH
were devoid of PrP
res (Fig. 2A).
Furthermore, soluble and insoluble PrP fractions from SBH
displayed slightly different banding patterns which suggested that
C2 was mainly insoluble, while soluble PrP contained FL-PrP and
the C1 fragment (Fig. 2A). Moreover, PrP
Sc dimers were clearly
segregated in the insoluble fraction (Fig. 2A). The differential
solubility of C1 and C2 in SBH was confirmed by the analysis of
deglycosylated PrP species (Fig. 2B), which showed that C1 was
completely soluble while C2 was mainly sedimented in the pellet
fraction (compare ‘‘S’’ and ‘‘P’’ lanes in Fig. 2B, left panel). With
the aim to mimic a situation comparable to that expected in
animals with pre-clinical disease, we also studied the differential
solubility of C1 and C2 after mixing equal amounts of NBH and
SBH (Fig. 2B). Indeed, under these conditions the PrP
C content is
increased compared to SBH, as can be seen by the higher
proportion of C1 in mixed NBH/SBH compared to SBH alone
(compare ‘‘Tot’’ lanes in the two panels of Fig. 2B). Also in this
condition, C1 was completely soluble and the pellet fraction was
enriched in C2 (compare ‘‘S’’ and ‘‘P’’ lanes in Fig. 2B, right
panel).
Finally, we investigated the efficacy of our solubility assay for
separating PrP
C and PrP
Sc in voles infected with other, non
scrapie-derived prion strains (Fig. 2C). For these experiments we
used voles infected with MM1 and MM2 sCJD [25]. In both
strains a substantial amount of PrP was found in the insoluble
fraction after detergent treatment and centrifugation. As already
observed in SBH, the banding patterns of insoluble and soluble
PrP were distinct, suggesting a specific precipitation of PrP species
associated to disease, namely C2 and PrP dimers (compare ‘‘S’’
and ‘‘P’’ lanes in Fig. 2C). Furthermore, after PK digestion, PrP
res
was strongly enriched in the pellets and virtually absent in the
supernatants.
Collectively, these findings strongly suggest that under the
experimental conditions described above we were able to
specifically precipitate PrP
Sc in brain homogenates from voles
infected with different prion strains.
Prion Strain Typing
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The near complete separation of PrP
C from PrP
Sc allowed us to
develop a procedure for biochemical strain typing based on the
conformational stability of PrP
Sc after exposure to GdnHCl. The
conformational solubility assay was set up by measuring PrP
Sc
solubility in positive brain homogenates treated for 1 hour with
increasing concentrations of GdnHCl.
As expected, in SBH PrP
Sc was solubilized by increasing GdnHCl
concentrations (Fig. 3A and B). Indeed, with concentrations of
GdnHCl equal or greater than 1.5 M, PrP
Sc was partially solubilised
and was progressively found in the supernatant instead of the pellet
(compare Fig. 3A and 3B). With 3.5 M GdnHCl, virtually all PrP from
SBH was found in the soluble fraction (Fig. 3A and 3B). The
solubilization of PrP
Sc was guanidine-dependent and dose-response
Figure 1. PrP species in healthy and scrapie-affected voles. A: Schematic representation of full length PrP (FL) and PrP fragments (C1 and C2)
generatedbya andb cleavages.ThelocationofSAF84,12B2 andSAF32epitopesused for theFL/C1/C2discrimination areshown. B andC: Normalbrain
homogenates (NBH) and scrapie brain homogenates (SBH) of voles were analyzed by western blot using SAF84 (B) and 12B2 (C). The samples, were
analyzed either before or after deglycosylation (N-Gly F) as indicated. The brackets on the left indicate the position of glycosylated and unglycosylated
bands of FL, C2 and C1: from 35 kDa to 27 kDa for FL, from 26 kDa to 18 kDa for C2 and from 24 kDa to 16 kDa for C1. These PrP species are reduced to
single unglycosylated PrP bands after deglycosylation, which are indicated by dashes on the right of the blots. In SBH, PrPSc dimers (Dim) are also
indicated. In NBH both C1andC2 were present, althoughC2 was poorlyrepresented; incontrastin SBHC2 fragmentwasthemost abundant PrP species
while C1 was barely detectable. Tissue equivalents(TE) loadedperlane were 0,15 mgand0.5 mg for samples respectively before andafter PK digestion.
Molecular weight markers were loaded into the last lane of each blot. The positions of MW markers are 15, 20, 25, 37 and 50 kDa.
doi:10.1371/journal.pone.0012723.g001
Prion Strain Typing
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12723curves enabled estimation of the concentration of GdnHCl able to
solubilise 50% of PrP
Sc ([GdnHCl]1/2). The [GdnHCl]1/2 value was
similar when estimated either in the pellet or in the supernatant
fractions (Fig. 3C). In contrast, PrP from NBH remained soluble within
the range of GdnHCl concentrations tested (Fig. 3D). Denaturation of
PrP
Sc was complete after incubation with GdnHCl for 1 hour, as very
similar denaturation curves were obtained when the treatment was
extended up to 4 hours (Fig. S1). When the denaturation curves where
measured in replica blots with mAbs recognising different PrP species,
namely SAF32 and SAF84 (see scheme in Fig. 1A), we obtained similar
[GdnHCl]1/2 values, which suggest that C2 and FL PrP
Sc share the
same conformational stability (Fig. S2).
We then studied the relationship between insolubility and PK-
resistance of PrP
Sc during denaturation. In order to investigate if
denaturation equally affects insolubility and PK-resistance, we
compared denaturation curves derived from the same SBH, either
obtained by insoluble PrP
Sc (CSSA) or by PK-resistant PrP
Sc
(CSA). As shown in Fig. 4, the curves of insoluble PrP
Sc (Fig. 4A)
and PrP
res (Fig. 4B) didn’t show differences (Fig. 4C), suggesting
that insolubility and PK-resistance were equally susceptible to
denaturation by GdnHCl. This finding was further confirmed in
experiments aimed at investigating whether, after denaturation,
solubilized PrP
Sc could partially preserve its resistance to
proteinase K. Indeed, after denaturation with 3 M GdnHCl,
soluble PrP was fully susceptible to protease digestion (Fig. 4D).
Conformational stability of scrapie, sCJD and gCJD PrP
Sc
from bank voles
Under the experimental conditions described above, we
investigated the potential of CSSA for differentiating prion strains.
As reported in previous studies [25,26] sCJD, gCJD and some
scrapie isolates present distinct and specific patterns of transmis-
sion in voles, based on survival times, lesion profiles, PrP
Sc
deposition and PrP
res biochemical properties. We have shown that
voles infected with MM1/MV1 sCJD and E200K gCJD isolates
were characterised by a PrP
res fragment of ,19 kDa, MM2 sCJD
showed a PrP
res fragment of ,17 kDa, while natural scrapie
isolates and murine scrapie ME7 were characterised by a PrP
res
fragment of ,18 kDa, intermediate between types 1 and 2 CJD.
Since these PrP
Sc types showed specific molecular characteris-
tics after PK digestion, we investigated the conformational stability
of PrP
Sc in voles infected with MM1 (n=4), MV1 (n=3) and
MM2 (n=5) sCJD, E200K gCJD (n=3) and scrapie SS7 (n=4).
Interestingly, CSSA revealed distinct denaturation profiles
(Fig. 5), with [GdnHCl]1/2 values ranging from 1.5 M to 3 M
(Table 1). Voles infected with MM1 sCJD, MV1 sCJD and E200K
gCJD showed the highest resistance to denaturation, with mean
[GdnHCl]1/2 values of 2.77 M, 2.88 M and 2.88 M, respectively.
In contrast, PrP
Sc from voles infected with MM2 sCJD was the most
sensitive (mean [GdnHCl]1/2 value of 1.63 M), while scrapie
infected voles showed intermediate [GdnHCl]1/2 values (2.10 M).
We then combined the individual curves within each group in order
to compare the denaturation profiles of the 5 groups (Fig. 5B).
Scrapie SS7 ([GdnHCl]1/2 value of 2.1060.02) and MM2 sCJD
([GdnHCl]1/2 value of 1.6160.03) showed strain specific denatur-
ation profiles,being significantly different from all othergroups (SS7
vs MV1, P=0.0037; SS7 vs MM1, P,0.0001; SS7 vs E200K,
P,0.0001; SS7 vs MM2, P,0.0001; MM2 vs MV1, P=0.0022;
MM2 vs MM1, P,0.0001; MM2 vs E200K, P,0.0001). In
contrast, MM1 sCJD, MV1 sCJD and E200K gCJD were not
significantly different among them (shared [GdnHCl]1/2 value of
2.7960.06, P=0.52) possibly representing a distinct strain, in
agreement with previous findings which showed comparable
phenotypes of disease in voles infected with these 3 isolates [25].
Figure 2. Separation of PrP
C and PrP
Sc in vole brain homog-
enates. A: Western blot analysis of soluble and insoluble PrP fractions
from normal brain homogenate (NBH) and scrapie brain homogenate
(SBH) of voles. Samples were centrifuged at 20000 g for 1 h in presence
of 2% sarcosyl, and supernatants (S) and pellets (P) were analysed
before (+) and after (2) PK treatment. Aliquots of samples before
centrifugation (Tot) were analysed too. TE per lane were 0,2 mg for
‘‘Tot’’ and ‘‘S’’ lanes, and 0.4 mg for ‘‘P’’ lanes. Brackets on the left
indicate the position of the FL, C1 and C2 PrP fragments. Dimers (Dim)
of PrP
Sc are indicated on the right in SBH blot. B: Western blot analysis
of soluble and insoluble PrP fractions from scrapie brain homogenate
(SBH) and an artificially mixed sample (SBH+NBH). Samples were
centrifuged as described and total (Tot), supernatant (S) and pellet (P)
fractions were deglycosylated. Full-length PrP (FL), C1 and C2 PrP
fragments are indicated on the left. In each lane, 0.02 mg TE were
loaded. C: Western blot analysis of soluble and insoluble PrP from brain
homogenates of voles infected with MM1 and MM2 sCJD. The samples
were treated as in panel A and total (Tot), supernatant (S) and pellet (P)
fractions were analysed with or without PK treatment. In each lane
0.3 mg TE were loaded. Brackets on the left indicate the position of the
FL, C1 and C2 fragments. Dimers (Dim) of PrP
Sc are indicated on the left.
A–C: Membranes were probed with SAF84. Molecular size markers are
shown in kilodaltons on the right of each panel.
doi:10.1371/journal.pone.0012723.g002
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Since we were interested in exploiting our conformational
solubility assay (CSSA) for strain discrimination in natural prion
diseases, we analysed 3 of the isolates used as inocula for
transmission to voles, namely the human MM1 and MM2 sCJD
isolates and the sheep scrapie SS7.
At first we tested the efficiency of separation of PrP
Sc from PrP
C
in human and sheep brain homogenates, under the same
experimental conditions used for vole brain homogenates. In all
samples, PrP
Sc was enriched in the pellet, as showed by the
segregation of PrP
res in the insoluble fraction and by the distinct
banding patterns shown by soluble and insoluble PrP (Fig. S3). In
negative sheep brain homogenates the fraction of PrP segregating
in the pellet was somewhat higher than in vole brains (.10% in
some experiment). However, this sedimented PrP
C was insensitive
to GdnHCl and thus did not interfere with our assay (Fig. S4).
When tested by CSSA, MM1 sCJD, MM2 sCJD and SS7 scrapie
revealed different susceptibilities to denaturation (Fig. 5A and B).
Interestingly, the rank order of conformational stability and the
[GdnHCl]1/2 values observed closely matched thosefound in the vole
counterpart, being MM1 sCJD the most resistant ([GdnHCl]1/2=
3.31 M),followed by scrapieSS7([GdnHCl]1/2=2.23M)andMM2
sCJD ([GdnHCl]1/2=1.63M).
Conformational stability of classical and Nor98 scrapie
isolates from sheep
In order to test the ability of CSSA for studying the
conformational stability of protease-sensitive PrP
Sc, we took
advantage of the recently described atypical scrapie strain,
Nor98 [3], which has been shown to induce the accumulation of
relatively protease-sensitive PrP
Sc [29]. As previously observed for
all other strains investigated, insoluble and soluble Nor98 PrP
Sc
showed different segregation of PrP species (Fig. 6). Interestingly
the 12 kDa PrP
res fragment, which is a characteristic feature of
Nor98 PrP
res [3,30], was observed before PK-digestion and
segregated with insoluble PrP, in a manner similar to what was
observed for C2 in all other strains. However, in Nor98 only a
minimal fraction of insoluble PrP was protease resistant (Fig. 6),
while PrP
res represented .90% of insoluble PrP in classical scrapie
(Fig. 6). These findings confirm that in Nor98 samples disease-
Figure 3. Conformational stability and solubility assay in healthy and diseased voles. A and B: Western blot analysis of scrapie brain
homogenate (SBH) after denaturation with various concentrations of GdnHCl and separation of insoluble (A) and soluble (B) fractions by
centrifugation. A: Immunoblot of pellets (P) at different concentrations of GdnHCl. In order to compare the fractions in the same blot, supernatant (S)
at 0 M GdnHCl was loaded too. In the pellets, insoluble PrP decreased with increasing concentrations of GdnHCl (M). In each lane 0.4 mg TE were
loaded. B: Immunoblot of supernatants at different concentrations of GdnHCl. In the first lane pellet (P) at 0 M GdnHCl was loaded too. In the
supernatant PrP increased with increasing GdnHCl. In each lane 0.4 mg TE were loaded. Note that the FL and C1 PrP fragments are present in the
supernatant after treatment with 0 M and 1 M GdnHCl, while the PrPSc-specific fragment C2 is visible in the supernatant from 1.5 M GdnHCl
onwards, in parallel with the decrease of insoluble PrP in panel A. C: The conformational stability of PrP
Sc in SBH was analysed by denaturation curves
best-fitted by plotting the fraction of PrP
Sc in the pellet (P) and in the supernatant (S), depicted in panel A and B respectively, as a function of GdnHCl
concentration. [GdnHCl]1/2 values were 1.92 M in the pellet and 1.91 M in the supernatant fraction. D: Western blot analysis of supernatants (S) at
different concentrations of GdnHCl from normal brain homogenate (NBH). In the first lane pellet (P) at 0 M GdnHCl was loaded. In NBH, PrP
C was
mostly in supernatant fraction and remained soluble at all GdnHCl concentrations tested. Samples were loaded as 0.4 mg tissue equivalent into each
lane. A, B, D: Membranes were probed with SAF84. Molecular size markers are shown in kilodaltons on the left of each panel.
doi:10.1371/journal.pone.0012723.g003
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low amounts of genuine PK-resistant PrP
Sc.
We then studied the conformational stability of Nor98 (n=5)
and classical (n=4) Italian field scrapie cases of different PrP
genotypes (Table 2). Classical scrapie samples gave denaturation
curves very similar to that of SS7, with [GdnHCl]1/2 values
ranging from 1.96 to 2.31 (Fig. 7 and Table 2). Nor98 samples
gave remarkably similar denaturation profiles, independently of
PrP genotype, and showed high sensitivity to GdnHCl denatur-
ation (Fig. 7), with [GdnHCl]1/2 values ranging from 1.26 to 1.43
(Table 2). Within group comparison didn’t show significant
differences among classical scrapie (shared [GdnHCl]1/2 value of
2.0960.11, P=0.52) and Nor98 (shared [GdnHCl]1/2 value of
1.3660.04, P=0.50). Comparison of the combined classical
scrapie and Nor98 denaturation profiles (Fig. 7B) gave statistically
significant different [GdnHCl]1/2 values (P,0.0001).
Discussion
The main pathogenetic event in TSEs involves the trans-
conformation of PrP
C to PrP
Sc, which leads to the accumulation of
detergent-insoluble and partially protease-resistant aggregates.
Thus, resistance to PK digestion and insolubility are the hallmarks
of PrP
Sc. However, previous studies on the molecular character-
ization of PrP
Sc were mainly focused on the PK-resistant core of
PrP
Sc, due to the difficulties in differentiating PrP
C from PrP
Sc in
infected brain homogenates. Notwithstanding, it is becoming
increasingly clear that insoluble but protease-sensitive isoforms of
PrP are involved in different animal and human prion diseases
[19,22,31,32,33,34,35]. These PrP isoforms have been detected by
several methods, including conformation-dependent immunoassay
[19,21,33], immunological capture [36,37], differential centrifu-
gation [31,32], thermolysin digestion [35] and cold PK digestion
[34].
Among the above-mentioned techniques able to detect sPrP
Sc,
the CDI was also reported to distinguish eight hamster prion
strains based on PrP
Sc conformation, by plotting the ratio of
antibody binding to denatured/native PrP as a function of the
concentration of PrP
Sc [19]. However, CDI depends on the
availability of monoclonal antibodies able to recognise buried
epitopes in PrP
Sc, such as the 3F4. We developed a protocol for
the molecular characterization of PrP
Sc aggregates which does not
rely on their protease resistance but is based on a conventional
procedure of differential centrifugation in the presence of
detergents and on the solubilization of PrP
Sc aggregates upon
denaturation with increasing concentrations of GdnHCl. Our
findings show that CSSA is reliable and straightforward, and that
it is able to discriminate PrP
Sc conformers associated with different
Figure 4. Relationship between PrP
Sc insolubility and resistance to PK. The same SBH was analyzed in parallel by CSSA (A) and CSA (B), and
the denaturation curves obtained were compared (C). A and B: Western blot analysis of insoluble PrP
Sc (A) and PK-resistant PrP
Sc (B) after
denaturation of homogenates with increasing concentrations of GdnHCl. In each lane 0.2 mg TE were loaded. The concentrations of GdnHCl were:
0.5, 1.0, 1.5, 2.0, 2.5, 3.0 and 4.0 M. C: Graph depicting the denaturation curves obtained by CSSA (panel A) and CSA (panel B). [GdnHCl]1/2 values
were 2.14 M and 2.23 M for CSSA and CSA, respectively. D: Western blot showing that PrP
Sc loses PK-resistance upon solubilization. In absence of
treatment with GdnHCl (0), total PrP (Tot) from SBH was resistant to PK digestion (compare PK- and PK+ lanes). After treatment with 3 M GdnHCl (3)
and differential centrifugation, most of PrP
Sc was found in the supernatant (S) and was also made PK-susceptible. In absence of treatment with
GdnHCl (0), the supernatant (S) contained normal PrP which was susceptible to PK. Note the different banding patterns in the supernatants
containing PrP
C (0) and solubilised PrP
Sc (3). A, B, D: Membranes were probed with SAF84. Molecular size markers are shown in kilodaltons on the left
of each panel.
doi:10.1371/journal.pone.0012723.g004
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of PrP
Sc from voles inoculated with MM1 sCJD, Scrapie and MM2 sCJD and from the respective human and sheep isolates. A: Representative western
blots of insoluble PrP
Sc from voles (left column) and natural hosts (on the right column) after treatment of homogenates with increasing
concentrations of GdnHCl. The concentrations of GdnHCl were: 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 and 4.0 M. TE loaded per lane were 0.2 mg for vole samples,
0.34 mg for human isolates and 0.125 mg for the scrapie isolate. Membranes were probed with SAF84 (vole samples and sheep scrapie) or with L42
(human isolates). B: Dose-response curves in vole strains, obtained by plotting the fraction of PrP
Sc remaining in the pellet as a function of GdnHCl
concentration and best-fitted and using a four parameter logistic equation. Individual curves were combined within each strain group (Scrapie, E200K
gCJD, MV1, MM1 and MM2 sCJD) in order to compare the denaturation profiles of the 5 groups. C: Dose-response curves from sheep and human
isolates, obtained by plotting the fraction of PrP
Sc remaining in the pellet as a function of GdnHCl concentration and best-fitted and using a four
parameter logistic equation. [GdnHCl]1/2 values of MM1, MM2 and scrapie isolates were 3,31 M, 1,63 M and 2,23 M respectively.
doi:10.1371/journal.pone.0012723.g005
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interesting advantages: i) it does not depend on the antibody used
and can be thus exploited to compare PrP
Sc conformational
stability in different species, ii) the proof that CDI is able to
discriminate prion strains in natural hosts is still lacking, while here
we show the potential of CSSA to be used in human and sheep
natural isolates.
In previous studies [20,38,39] a conformational stability assay
(CSA) able to discriminate PrP
Sc conformers was set up by
measuring the extent of loss in protease resistance as a function of
increased exposure to GdnHCl. This method proved to be very
helpful for molecular strain typing in different species [40,41,42]
and was also recently exploited for investigating some basic
mechanisms of prion replication [39]. The protocol that we
developed is conceptually similar to CSA, as it derives information
on the conformational stability of PrP
Sc aggregates. Indeed, we
showed that CSA and CSSA gave very similar denaturation
profiles in vole-adapted scrapie brain homogenates (see Fig. 4).
However, we believe that CSSA represents a step forward in prion
molecular typing and offers several advantages compared with
previously used protocols. With CSA, in fact, susceptibility to PK
is exploited to distinguish denaturated from native PrP
Sc.
However, different prion strains may have distinct susceptibilities
to PK, while CSA uses the same PK concentration to derive the
level of PrP
Sc denaturation in different strains. Furthermore, when
performing CSA it is necessary to dilute the GdnHCl to allow the
activity of proteolytic enzyme. However, it is known that PrP
Sc
unfolding can be a partially reversible phenomenon and, as
reported, the dilution of the denaturant could restore the original
protease-resistance of PrP
Sc [43]. With CSSA this problem was
circumvented by avoiding any change in denaturant concentration
during the assay. Indeed, the denaturation step is followed by the
centrifugal separation of soluble and insoluble fractions, which is
performed under conditions identical to the denaturation step.
Most importantly, CSSA allowed the characterization of
protease-sensitive PrP
Sc, and thus the direct comparison of the
conformational stabilities of TSE strains associated with protease-
sensitive and protease-resistant PrP
Sc. We investigated the
potential of CSSA for strain typing of ovine field isolates of
Nor98, which are characterised by high amounts of insoluble
sPrP
Sc [29, present paper]. Our findings seem very encouraging,
since Nor98 samples displayed a distinct denaturation profile,
although the isolates derived from sheep of various PrP genotypes
and presumably at different stage of the disease. Furthermore,
Nor98 samples were easily discriminated from classical scrapie,
which represents a different strain. Thus CSSA enabled
characterization of the conformational stability of a protease
sensitive strain, for which methods based on proteolysis would
have characterised only a minimal amount of PrP
Sc present in the
brain homogenate. This is promising in view of recent studies
[21,35] showing that in sCJD and vCJD isolates, as much as 90%
of PrP
Sc in the brains was estimated to be sPrP
Sc. Furthermore the
recent discovery of protease sensitive prionopathy (PSPr), a
previously unrecognised human prion disease [22], might suggest
that prion diseases characterised by protease-sensitive PrP isoforms
are more frequent than previously thought. Brain homogenates
from PSPr cases were reported to contain mainly a protease
sensitive form of insoluble PrP, accompanied by low amounts of
typical protease-resistant PrP [22], similarly to our findings in
Nor98 samples. It would be interesting to investigate the potential
of CSSA for characterising these human protease-sensitive disease-
related isoforms of PrP.
Another interesting feature of CSSA is that, by avoiding PK
treatment, it allowed the characterization of FL-PrP
Sc, including
the N-terminus which is cleaved upon PK digestion. Besides FL-
PrP, in vivo trimmed PrP
Sc fragments were selectively precipitated
and thus CSSA also conveyed information on their conformational
stability. These fragments comprised C2 C-terminal fragments in
scrapie and sCJD isolates, as well as the 12 kDa internal fragment
Table 1. Conformational stability of PrP
Sc in vole-adapted
sCJD, gCJD and scrapie.
Inoculum Vole ID
[GdnHCl]1/2
(M) ± SEM
[GdnHCl]1/2 (M)
(mean ± SD)
MM1 sCJD 304/2 2.7360.17 2.7760.13
304/4 2.6360.12
304/8 2.7660.11
304/14 2.9460.19
MV1 sCJD 272/1 3.0560.29 2.8860.17
272/4 2.8760.36
272/8 2.7260.11
MM2 sCJD 270/6 1.4560.01 1.6360.11
270/7 1.7160.07
350/3 1.6060.09
350/5 1.6960.04
350/14 1.6960.06
E200K gCJD 271/4 2.7360.15 2.8860.13
271/5 2.9960.25
271/6 2,9160.18
scrapie SS7 388/7 2.2260.04 2.1060.13
388/9 2.1660.03
388/10 1.9260.02
388/11 2.0860.03
doi:10.1371/journal.pone.0012723.t001
Figure 6. Separation of soluble and insoluble PrP fractions in
classical scrapie and Nor98. Western blot analysis of classical scrapie
and Nor98 ovine isolates. Supernatant (S) and pellet (P) fractions were
analysed with (+) or without (2) PK treatment. In each lane 0.8 mg TE
were loaded. Molecular size markers are shown in kilodaltons on the left
of the blot. Membrane was probed with L42.
doi:10.1371/journal.pone.0012723.g006
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PrP, also by means of differential antibody binding (data not
shown; see for example Fig. S2). This is interesting because it
enables a comparison of the conformational properties of PrP
Sc
aggregates made-up of FL-PrP or in vivo trimmed PrP
Sc fragments.
In situ epitope-mapping of PrP
Sc, indeed, showed that FL and C2
PrP
Sc aggregates have different cellular localizations [44].
Furthermore, by analysing thermolysin-resistant PrP
Sc in sheep
scrapie and BSE isolates, Owen and colleagues have recently
shown the potential of C2 fragments for strain typing [45].
The main potential drawback of CSSA might be the incomplete
separation or PrP
C and PrP
Sc. Herein, we developed a protocol
able to minimise this problem, notwithstanding 1–4% of PrP
C in
brain homogenates from healthy voles was found in the pellet
under our working conditions. There are however several lines of
evidence suggesting that this potential drawback did not interfere
with CSSA results. We have shown that brain homogenates from
clinically affected voles contain low levels of soluble PrP (bona fide
PrP
C) (see Fig. 2). Based on the results obtained with NBH, less
than 5% of PrP
C is expected to be found in the pellet; on the other
hand, in diseased brains bona fide PrP
C was 5–30% of total PrP.
From these considerations, it can be argued that the PrP
Sc/PrP
C
ratio in the pellet should be higher than 2 orders of magnitude,
which represents the working range of CSSA. Furthermore, we
obtained clear-cut differential solubility of PrP
C and PrP
Sc even
after increasing the PrP
C/PrP
Sc ratio in the homogenate, by
mixing SBH with NBH (Fig. 2). Most importantly, we found that
the sedimented PrP
C fraction was insensitive to denaturation (Fig.
S4) and thus it does not interfere with CSSA.
We investigated the potential of CSSA for strain discrimination
by analysing vole-adapted strains deriving from human sCJD,
gCJD and sheep scrapie which we have previously shown to give
distinct strains in voles [25,26]. In previous studies we have shown
that voles infected with MM1/MV1 sCJD and E200K gCJD
isolates showed identical transmission patterns and were char-
acterised by an unglycosylated PrP
res fragment of ,19 kDa, while
MM2 sCJD showed an unglycosylated PrP
res fragment of
,17 kDa. In contrast, all Italian scrapie isolates studied so far
[26,46], as well as the murine scrapie strain ME7 [25], were
characterised by the accumulation of an unglycosylated PrP
res with
a molecular weight (,18 kDa) intermediate between CJD types 1
and 2, upon transmission to voles. These different PrP
res types
derive from different PK-cleavage sites of PrP
Sc, which in turn are
believed to reflect distinct conformations of PrP
Sc aggregates. With
CSSA we showed that these three PrP
res types are actually
characterised by PrP
Sc aggregates with distinct susceptibilities to
denaturation by GdnHCl. Indeed, PrP
Sc from voles infected with
MM1 sCJD, MV1 sCJD and E200K gCJD, characterised by
19 kDa PrP
res, showed the highest resistance to denaturation,
while sCJD MM2, characterised by 17 kDa PrP
res, was the most
susceptible and scrapie SS7, that was characterised by 18 kDa
PrP
res, displayed intermediate susceptibility. Interestingly, the
within group variability of [GdnHCl]1/2 values was very low (see
table 1) and allowed statistical comparisons among the different
groups, which strengthened the view that [GdnHCl]1/2 values
reflect strain-specific rather than individual PrP
Sc properties.
It has been recently suggested that the conformational stability
of PrP
Sc is directly proportional to the length of the incubation
time in mice [39]. On this point, it is worth noting that our results
in voles, although based on only 5 isolates, seem to contradict this
conclusion. Indeed, the lowest conformational stability was
associated with prions with the longest survival times, i.e. MM2
sCJD with a survival time of ,330 days post-inoculation (dpi),
while scrapie SS7 (survival time of ,90 dpi) and MM1/MV1
sCJD (survival time of ,130 dpi) showed higher conformational
stabilities and shorter survival times compared to MM2 sCJD.
Further studies with an extended panel of isolates are needed to
investigate if the direct relationship between conformational
stability and incubation time observed in mice holds true also
for vole prions.
We also explored the potential of CSSA for strain typing of
natural prion diseases. To this aim we analysed three of the human
and sheep isolates which were used for bioassay in vole.
Interestingly, we found that the two isolates from MM1 sCJD
and MM2 sCJD patients could be easily discriminated by their
conformational stabilities, with MM1 sCJD displaying lower
susceptibility to denaturation compared to MM2 sCJD
([GdnHCl]1/2 values of 3,31 M for MM1 sCJD and 1,63 M for
MM2 sCJD). These findings compare well with previous studies by
CSA, which showed that PrP
Sc associated with MM1 sCJD was ,
2-fold more stable than that of MM2 sCJD, with [GdnHCl]1/2
values of 2,76 M and 1,63 M for MM1 sCJD and MM2 sCJD
[40]. Of course, this needs confirmation in a larger set of isolates.
Furthermore, this approach allowed us to compare the
conformational stability of prions in their natural host and after
transmission to voles. It has been previously shown that prion
strains can either maintain their biological properties or mutate
upon propagation in a new host species [10]. More recently it was
reported that a change in conformation was accompanied by the
emergence of a new prion strain during interspecies transmission,
Table 2. Conformational stability of PrP
Sc in sheep field prion isolates.
Strain Sheep ID Age (y) Clinical signs PrP Genotype* [GdnHCl]1/2 (M) [GdnHCl]1/2 (M) (mean±SD)
Classical scrapie ES8/09/3 2 Yes ALRQ/ALRQ 2.27 2.2060.16
ES8/09/1 6 No ALRQ/ALHQ 1.96
241/105 3 No ALRQ/ALRQ 2.27
211/26 3 Yes ALRQ/ALRQ 2.31
Nor98 ES36/08/4 12 No ALHQ/ALRR 1.26 1.3260.07
ES35/07/2 9 No ALRQ/ALHQ 1.26
ES10/07/7 12 No AFRQ/AFRQ 1.35
ES18/07/2 5 No ALRQ/ALHQ 1.31
ES19/07/23 7 No ALRR/ALRR 1.43
*amino acids at codons 136, 141, 154 and 171.
doi:10.1371/journal.pone.0012723.t002
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Sc was preserved when a
strain ‘‘bred true’’ in the new host [38]. Our findings show that the
rank order of conformational stability of sCJD and scrapie isolates
was generally preserved upon adaptation in voles (see Fig. 5). In
particular, the conformational stability of MM2 sCJD was
identical before and after transmission in voles. We have also
previously reported that MM2 sCJD, and to a lower extent MM1
sCJD, encountered a very low transmission barrier to voles when
compared to several other prion strains [25]. These observations
may suggest that MM2 and possibly MM1 sCJD faithfully
propagated their strain properties upon transmission in voles.
The ‘‘conformational selection’’ model, postulates that host PrP
C
primary structure influences which of the portfolio of possible
PrP
Sc types are thermodynamically preferred during propagation
[47]. In this model, the transmission barrier is determined by the
degree of overlap between the subset of PrP
Sc types allowed or
preferred by PrP
C in the host and donor species. It can be thus
speculated that the vole PrP sequence is prone to adopt some
human PrP
Sc conformations and we have previously shown that
this property may reside in the presence of some peculiar amino
acid at relevant positions of vole PrP [46,48].
Finally, we exploited CSSA for discriminating sheep field prion
isolates, showing that this method is valuable for strain
discrimination in natural hosts. Indeed, the conformational
stability of prions was strongly associated with the strain, either
classical scrapie or Nor98, and did not depend on individual
properties such as age, clinical stage or PrP genotype (see table 2).
Although preliminary, these findings suggest that CSSA might be
exploited as complementary approach for increasing the discrim-
inatory power of strain typing in small ruminant TSEs. Studies
with natural and experimental TSEs, including sheep BSE and
CH1641-like isolates, are underway.
Materials and Methods
Terminology
Throughout the manuscript we used ‘‘prion’’ to refer to the
infectious agent of TSEs, ‘‘PrP
Sc’’ to refer to the abnormal disease-
associated PrP isoform, ‘‘rPrP
Sc’’ to refer to the protease-resistant
fraction of PrP
Sc, ‘‘sPrP
Sc‘‘ to refer to the protease-sensitive
fraction of PrP
Sc and ‘‘PrP
res’’ to refer to protease-resistant PrP
Sc
fragments deriving from rPrP
Sc trimming by proteinase K.
Natural TSE isolates
Human brain tissues were from cerebral cortices of two sCJD
cases (MM1 and MM2 types) previously characterised by vole
bioassay [25].
The medulla oblongata of SS7 scrapie was obtained from an
ARQ/ARQ Sarda sheep with clinical scrapie reported in Italy in
1997 and previously characterised by vole bioassay [26]. All others
sheep brain tissues were from Italian field cases detected by active
and passive surveillance and characterised by discriminatory
western blotting for molecular strain typing and by complete
sequencing of the PRNP open reading frame, according to
published protocols [49,50]. The details of these TSE cases are
reported in Table 2.
Vole samples
Brain tissues were obtained from voles infected with vole-adapted
human and sheep TSEs as previously reported [25,26]. The passage
number and mean survival times 6 standard deviation of the vole
groups from which the samples used in the present study derived were
as follows: sCJD MM1, second passage, 12968 dpi; sCJD MV1,
second passage, 12861 5d p i ;s C J DM M 2 ,s e c o n dp a s s a g e ,3 3 9 627
dpi; sCJD MM2, third passage, 323641 dpi; gCJD E200K, second
passage, 143612 dpi; scrapie SS7, third passage, 9365 dpi.
Separation of PrP
Sc and PrP
C by differential
centrifugation
Brain homogenates (20% w/v) were prepared in 100 mM Tris-
HCl with Complete protease inhibitor cocktail [Roche] at pH 7.4.
The homogenates were either used directly or stored at 220uC.
Figure 7. CSSA of classical scrapie and Nor98 isolates. A:
Representative western blots of insoluble PrP after denaturation with
increasing concentrations of GdnHCl in classical scrapie (ARQ/AHQ) and
Nor98 (ARR/AHQ) isolates. The concentrations of GdnHCl were: 0, 0.5,
1.0, 1.5, 2.0, 2.5, 3.0 and 4.0 M. TE loaded per lane were 0.125 mg for
classical scrapie and 0.3 mg for Nor98. Membranes were probed with
L42. Molecular size markers are shown in kilodaltons on the right of
each blot. B: Dose-response curves of Nor98 and classical scrapie,
obtained by plotting the fraction of PrP
Sc remaining in the pellet as a
function of GdnHCl concentration and best-fitted and using a four
parameter logistic equation. Individual curves were combined within
each strain group (Scrapie and Nopr98) in order to compare the
denaturation profiles of the two groups. Individual [GdnHCl]1/2 values
are shown in Table 2.
doi:10.1371/journal.pone.0012723.g007
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C/PrP
Sc separation were
set up in vole brain homogenates by studying the effect of different
detergents, centrifugal force and time of centrifugation.
Brain homogenates (3% to 12% w/v) were added with equal
volumes of different buffers (100 mM Tris-HCl at pH 7.4
containing Sarcosyl 4% or 2%; 100 mM Tris-HCl at pH 7.4
containing NaDoc 1%, NP40 1%; 100 mM Tris-HCl at pH 7.4
containing Triton X-100 2%) and incubated for 1 hour at 37uC
with gentle shaking. Then samples were centrifuged at 10000 to
20000 g for 1 h or 2 h. The obtained pellets were re-suspended
with 100 mM Tris-HCl (pH 7.4) containing the relevant deter-
gent. The experimental conditions then used throughout the paper
in vole, sheep or human brain tissues included solubilisation in
100 mM Tris-HCl at pH 7.4 containing sarcosyl 2% and
centrifugation at 20000 g for 1 h. For each of the different
experimental conditions tested, equivalent aliquots of brain
homogenate before centrifugation, along with supernatant and
pellet fractions, were analysed by western blot either with or
without PK digestion.
Conformational stability and solubility assay
Aliquots of brain homogenates (3% to 6% w/v) were added
with an equal volume of 100 mM Tris-HCl (pH 7.4) containing
sarcosyl 4% and incubated for 1 h at 37uC with gentle shaking.
Aliquots of 100 ml were treated with 100 ml of guanidine
hydrochloride (GdnHCl) solutions with a final concentration
ranging from 0 to 4.0 M. GdnHCl stock solutions were prepared
from an 8 M solution (Pierce) diluted in water. After treatment
with GdnHCl for 1 h at 37uC with gentle shaking, samples were
centrifuged at 20000 g for 1 h at 22uC. Pellets were re-suspended
in 90 ml NuPage LDS Sample Buffer (Invitrogen) and 10 ml
NuPage Sample Reducing Agent (Invitrogen). Aliquots of
supernatants were precipitated with 4-fold volume excess of pre-
chilled methanol 30 min at 220uC, centrifuged at 15000 g for
30 min at 4uC and then were re-suspended in 90 ml NuPage LDS
Sample Buffer (Invitrogen) and 10 ml NuPage Sample Reducing
Agent (Invitrogen). Supernatant and pellet fractions were analysed
by Western blotting.
Individual denaturation curves were analyzed and best-fitted by
plotting the fraction of PrP
Sc remaining in the pellet as a function
of GdnHCl concentration, and using a four parameter logistic
equation (GraphPad Prism). In order to fit denaturation curves for
each prion strain, the mean fraction of PrP
Sc remaining in the
pellet 6 SD were plotted. Statistical comparison of [GdnHCl]1/2
values were made by comparing the best-fit value for each data set
with GraphPad Prism. This was performed by either fitting each
data set independently or doing a global fit with a shared
[GdnHCl]1/2 value, and then the results were compared with an F
test. The simpler model was selected unless the extra sum-of-
squares F test had a P value,0.05.
Digestion with proteinase K after denaturation with
GdnHCl
Aliquots of the same brain homogenate were treated in parallel
according to CSSA and conformational stability assay (CSA)
protocols. The CSA was performed as described [20], with minor
modifications. Aliquots of brain homogenates (6% w/v) were
added with an equal volume of 100 mM Tris-HCl (pH 7.4)
containing sarcosyl 4% and incubated for 1 h at 37uC with gentle
shaking. Aliquots of 50 ml were added with 50 ml of GdnHCl to
give a final concentration ranging from 0 to 4.0 M. After 1 h of
incubation at 37uC all samples were diluted to a final
concentration of 0.4 M GdnHCl. Proteinase K (50 mg/ml) was
added and the samples were incubated for 1 h at 37uC with gentle
shaking. The reaction was stopped with 3 mM PMSF (Sigma).
Aliquots of samples were added with an equal volume of
isopropanol/butanol (1:1 v/v) and centrifuged at 20000 g for
5 min. Pellets were re-suspended in NuPage LDS Sample Buffer
(Invitrogen) and were analysed by Western Blotting.
Western blot analysis
Electrophoresis and Western blotting were performed as
previously described [25]. Samples were denatured by adding
NuPage LDS Sample Buffer (Invitrogen, Carlsbad, California,
United States) and NuPage Sample Reducing Agent (Invitrogen),
and heating for 10 min at 90uC. After centrifugation at 10000 g
for 5 min each sample was loaded onto 12% bis-Tris polyacryl-
amide gels (Invitrogen). After electrophoresis and Western blotting
on PVDF membranes (Immobilon-P; Millipore, Bedford, MA,
USA), the blots were processed by SNAP i.d.
TM Protein Detection
System (Millipore) as described by the manufacturer instructions.
The monoclonal antibodies used, their epitopes on sheep PrP
and the working dilutions were as follow: SAF84, PrP residues
167–173, 1.2 mg/ml; L42, PrP residues 148–153, 0.28 mg/ml;
12B2, PrP residues 93–97, 2.4 mg/ml and SAF32, PrP octarepeat,
2.4 mg/ml. Horseradish peroxidase-conjugated anti-mouse immu-
noglobulin (Pierce Biotechnology, Rockford, Illinois, United
States) was used as secondary antibody (1:13000).
The membranes were developed with an enhanced chemilu-
minescence method (SuperSignal Femto, Pierce). Chemilumines-
cence signal was detected with the VersaDoc imaging system (Bio-
Rad) and was quantified by QuantityOne software (Bio-Rad).
Deglycosylation was performed by adding 18 ml of 0.2 M
sodium phosphate buffer (pH 7.4) containing 0.8% Nonidet P40
(Roche) and 2 ml (80 U/ml) di N-Glycosidase F (Roche) to 5 mlo f
denaturated samples and by incubating overnight at 37uC with
gentle shaking. Samples were then analysed by Western blotting as
described above.
Supporting Information
Figure S1 Effect of denaturation time on CSSA. Dose-response
curves of insoluble PrP from brain homogenates of voles infected
with scrapie SS7 (top panel) and MM1 sCJD (bottom panel) after
treatment with increasing concentrations of GdnHCl for 1, 2 or
4 hours. Denaturation curves were best-fitted by plotting the
fraction of PrP remaining in the pellet as a function of GdnHCl
concentration. SS7 and MM1 didn’t reveal differences based on
time of treatment and showed the same [GdnHCl]1/2 values at 1,
2 and 4 hours (2.1 M for SS7 e 3 M for MM1 sCJD).
Found at: doi:10.1371/journal.pone.0012723.s001 (0.13 MB TIF)
Figure S2 CSSA with different mAbs. A: Representative
western blots of insoluble PrP from vole infected with E200K
gCJD after denaturation with increasing concentrations of
GdnHCl. Replica blots were probed with SAF84 (top) and
SAF32 (bottom), as indicated on the left of the blot. The
concentrations of GdnHCl were: 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0
and 4.0 M. In each lane 0.2 mg TE were loaded. B: Dose-
response curves derived from the blots in panel A, obtained by
plotting the fraction of PrP remaining in the pellet as a function of
GdnHCl concentration and best-fitted and using a four-parameter
logistic equation.
Found at: doi:10.1371/journal.pone.0012723.s002 (0.57 MB TIF)
Figure S3 Separation of soluble and insoluble PrP fractions from
human and sheep isolates. Western blot analysis of soluble and
insoluble PrP from brain homogenates of sheep with classical
scrapie and human with MM1 sCJD. Samples were centrifuged at
Prion Strain Typing
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and pellets (P) were analysed with (+) or without (2) PK treatment.
Aliquots of samples before centrifugation (Tot) were analysed too.
TE loaded per lane were 0.2 mg for classical scrapie and 0.15 mg
for MM1 sCJD. Scrapie membrane was probed with SAF84 and
MM1 sCJD membrane was probed with L42.
Found at: doi:10.1371/journal.pone.0012723.s003 (0.48 MB TIF)
Figure S4 Separation of soluble and insoluble PrP fractions from
sheep normal brain homogenates. A: Western blot analysis of
soluble and insoluble PrP fractions from a representative sheep
negative brain homogenate. Total PrP (Tot) and PrP from
supernatant (S) and pellet (P) fractions were analysed with (+)o r
without (2) PK treatment. TE loaded per lane were 0.2 mg. B:
Western blot analysis of insoluble PrP from sheep negative and
scrapie brain homogenates after denaturation with increasing
concentrations of GdnHCl, either after normal (top panel) or long
(bottom panel) exposure times. The concentrations of GdnHCl
were: 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 and 4.0 M. TE loaded per lane
were 0.12 mg. A and B: Membranes were probed with SAF84.
Found at: doi:10.1371/journal.pone.0012723.s004 (0.69 MB TIF)
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